⌘K
Loading ticker…
Erasca, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Erasca, Inc. Common Stock (ERAS) has a 3-month relative strength percentile of 51 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 99. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 8.5%, relative volume 3.24×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
51 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
ERAS is in a stage 2 uptrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 18.1% / 80.1%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
ERAS is held by 5 ETFs as of Mar 2026. Top owner: VTI at 0.01% weight, $134M notional. Top 3 carry $286M.
Top 5 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.01% | $134M |
| XBIState Street SPDR S&P Biotech ETF | 1.03% | $77M |
| IWMiShares Russell 2000 ETF | 0.10% | $75M |
| VXFVanguard Extended Market ETF | 0.05% | $43M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.01% | $5M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ERAS Jan avg: 32.26% median: -14.39% win: 25% σ: 100.47% n: 4 2022-04-12 → 2026-05-29 | ERAS Feb avg: 8.74% median: 9.99% win: 50% σ: 32.95% n: 4 2022-04-12 → 2026-05-29 | ERAS Mar avg: -2.85% median: -6.72% win: 25% σ: 15.89% n: 4 2022-04-12 → 2026-05-29 | ERAS Apr avg: -9.40% median: -8.31% win: 20% σ: 15.16% n: 5 2022-04-12 → 2026-05-29 | ERAS May avg: 2.89% median: -1.81% win: 40% σ: 20.60% n: 5 2022-04-12 → 2026-05-29 | ERAS Jun avg: -2.76% median: -2.25% win: 50% σ: 5.98% n: 4 2022-04-12 → 2026-05-29 (current) | ERAS Jul avg: 18.98% median: 22.45% win: 75% σ: 18.97% n: 4 2022-04-12 → 2026-05-29 | ERAS Aug avg: 5.11% median: 4.53% win: 50% σ: 12.55% n: 4 2022-04-12 → 2026-05-29 | ERAS Sep avg: -1.04% median: -9.53% win: 25% σ: 27.64% n: 4 2022-04-12 → 2026-05-29 | ERAS Oct avg: 6.97% median: 7.88% win: 75% σ: 9.55% n: 4 2022-04-12 → 2026-05-29 | ERAS Nov avg: 1.85% median: 1.42% win: 50% σ: 24.57% n: 4 2022-04-12 → 2026-05-29 | ERAS Dec avg: -3.13% median: 2.56% win: 50% σ: 31.05% n: 4 2022-04-12 → 2026-05-29 |